Trial Profile
Patient Compliance During PegIntron [peginterferon alfa-2b] (Injection Pen) and Rebetol [ribavirin] Combination Therapy in Chronic Hepatitis C.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 10 Oct 2011 Actual patient number is 294 according to ClinicalTrials.gov.
- 06 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Dec 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.